Last 12 months
Inside the activity.
0 purchase rows · 279 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 31 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 111 |
| Feb 2026 | 0 | 11 |
| Mar 2026 | 0 | 106 |
| Apr 2026 | 0 | 14 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC |
KEATING LAURIEEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 25,000 | $42.22 | $1,055,500.00 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 2 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 27, 2020 Filed Jan 29, 2020 21:03 UTC |
KEATING LAURIEEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 9,374 | $42.22 | $395,770.28 |
DisclosureSEC source: 0001735276-20-000002 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,632 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Read SEC document |
| January 27, 2020 Filed Feb 12, 2020 21:02 UTC Amendment |
KEATING LAURIEEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 3,663 | $77.40 | $283,516.20 |
DisclosureSEC source: 0001735276-20-000013 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,258 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction reported on this Form 4 was made pursuant to Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2019. Reflects shares acquired upon the exercise by the reporting person of a stock option on January 27, 2020. This acquisition was inadvertently omitted from the Form 4 filed on January 29, 2020 which reported both the exercise of the stock option and the subsequent sale of such acquired shares. Read SEC document |
| January 03, 2020 Filed Feb 28, 2020 21:07 UTC |
Poulton Jeffrey V.Chief Financial Officer
|
OtherCommon Stock | 19 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-20-000032 · edgardoc.xml · nonDerivative · entry 1 Poulton Jeffrey V. · CIK 0001782962 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 19 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:04 UTC |
Vaishnaw AkshayPresident, R&D
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,333 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000123 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 8,333 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:03 UTC |
KEATING LAURIEEVP, Chief Legal Officer
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 4,583 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000121 · edgardoc.xml · derivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,166 Underlying: Common Stock · 4,583 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:04 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 17,498 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000122 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,996 Underlying: Common Stock · 17,498 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:02 UTC |
Greene Barry EPresident
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 9,999 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000119 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,998 Underlying: Common Stock · 9,999 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:03 UTC |
Greenstreet YvonneChief Operating Officer
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,333 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000120 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 8,333 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the second performance criterion was met and the option vested as to the second one third of the shares as of December 23, 2019. Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:25 UTC |
Greenstreet YvonneChief Operating Officer
|
Tax withholdingCommon Stock | 3,208 | $120.61 | $386,916.88 |
DisclosureSEC source: 0001735276-19-000113 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,208 Read SEC document |
| December 12, 2019 Filed Dec 13, 2019 21:25 UTC |
Greenstreet YvonneChief Operating Officer
|
GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000113 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,416 F1 · kind: On June 29, 2017, the reporting person was granted a restricted stock unit (RSU) to purchase shares of ALNY common stock. One half of the shares subject to release vested upon the achievement of each of two specific commercial events as approved by the compensation committee of the company. The compensation committee determined that the second performance criterion was met and therefore the second and final half of the shares vested as of December 12, 2019. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:08 UTC |
Greene Barry EPresident
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 9,999 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000110 · edgardoc.xml · derivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,999 Underlying: Common Stock · 9,999 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:07 UTC |
KEATING LAURIEEVP, Chief Legal Officer
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 4,583 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000109 · edgardoc.xml · derivative · entry 3 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,583 Underlying: Common Stock · 4,583 shares Expires 2028-03-01 F2 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:06 UTC |
Greenstreet YvonneChief Operating Officer
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,333 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000108 · edgardoc.xml · derivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:05 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 17,498 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000107 · edgardoc.xml · derivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Underlying: Common Stock · 17,498 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| November 22, 2019 Filed Nov 26, 2019 21:05 UTC |
Vaishnaw AkshayPresident, R&D
|
GrantPerformance Stock Option 2017 (right to buy) · Derivative | 8,333 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-19-000106 · edgardoc.xml · derivative · entry 1 Vaishnaw Akshay · CIK 0001458494 · President, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2028-03-01 F1 · kind: On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One third of the shares subject to the option vest upon the achievement of each of three specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the first performance criterion was met on November 22, 2019 and the option vested as to the first one third of the shares as of such date. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC |
Greenstreet YvonneChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 2,154 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · derivative · entry 6 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 2,154 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC |
Greenstreet YvonneChief Operating Officer
|
Exercise / conversionPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · derivative · entry 5 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC |
Greenstreet YvonneChief Operating Officer
|
SaleCommon Stock | 8,404 | $105.00 | $882,420.00 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · nonDerivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,916 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC |
Greenstreet YvonneChief Operating Officer
|
Exercise / conversionCommon Stock | 6,250 | $42.22 | $263,875.00 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · nonDerivative · entry 2 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:05 UTC |
Greenstreet YvonneChief Operating Officer
|
Exercise / conversionCommon Stock | 2,154 | $42.22 | $90,941.88 |
DisclosureSEC source: 0001735276-19-000099 · edgardoc.xml · nonDerivative · entry 1 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 20, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $30.09 | $0.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · derivative · entry 9 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2023-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $9.30 | $0.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · derivative · entry 8 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.33 | $0.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · derivative · entry 7 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2022-06-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $9.14 | $0.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · derivative · entry 6 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2020-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. F2 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
SaleCommon Stock | 75,000 | $100.00 | $7,500,000.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 5 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
Exercise / conversionCommon Stock | 15,000 | $30.09 | $451,350.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 4 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
Exercise / conversionCommon Stock | 15,000 | $11.33 | $169,950.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 3 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
Exercise / conversionCommon Stock | 15,000 | $9.30 | $139,500.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 2 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:06 UTC |
Fanucci MarshaDirector
|
Exercise / conversionCommon Stock | 30,000 | $9.14 | $274,200.00 |
DisclosureSEC source: 0001735276-19-000100 · edgardoc.xml · nonDerivative · entry 1 Fanucci Marsha · CIK 0001298814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2018. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC |
SHARP PHILLIP ADirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · derivative · entry 6 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2019-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC |
SHARP PHILLIP ADirector
|
SaleCommon Stock | 810 | $92.66 | $75,054.60 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 4 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,633 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. F4 · price: Sale prices ranged from $92.53 to $92.74. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC |
SHARP PHILLIP ADirector
|
SaleCommon Stock | 8,631 | $91.97 | $793,793.07 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 3 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,443 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. F3 · price: Sale prices ranged from $91.50 to $92.48. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC |
SHARP PHILLIP ADirector
|
SaleCommon Stock | 5,559 | $91.17 | $506,814.03 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 2 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,074 F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. F2 · price: Sale prices ranged from $90.50 to $91.49. Read SEC document |
| November 18, 2019 Filed Nov 20, 2019 21:17 UTC |
SHARP PHILLIP ADirector
|
Exercise / conversionCommon Stock | 15,000 | $16.43 | $246,450.00 |
DisclosureSEC source: 0001735276-19-000096 · edgardoc.xml · nonDerivative · entry 1 SHARP PHILLIP A · CIK 0001226295 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2019. The 15,000 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 20:04 UTC |
Greene Barry EPresident
|
OtherCommon Stock | 5,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · nonDerivative · entry 4 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 3,486 F2 · kind: These shares were distributed in October 2019 to the reporting person from the "Barry E. Greene Qualified Annuity Interest Trust" (GRAT). F3 · ownership.nature: Represents remaining shares held by the "Barry E. Greene Qualified Annuity Interest Trust" (GRAT), of which Barry E. Greene is the sole Trustee Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 20:04 UTC |
Greene Barry EPresident
|
OtherCommon Stock | 5,544 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · nonDerivative · entry 3 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,482 F2 · kind: These shares were distributed in October 2019 to the reporting person from the "Barry E. Greene Qualified Annuity Interest Trust" (GRAT). Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 20:04 UTC |
Greene Barry EPresident
|
Exercise / conversionStock Option (right to buy) · Derivative | 58,913 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · derivative · entry 6 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,913 shares Expires 2019-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019. The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019. F5 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 20:04 UTC |
Greene Barry EPresident
|
SaleCommon Stock | 58,913 | $89.99 | $5,301,580.87 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · nonDerivative · entry 2 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,938 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019. The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 20:04 UTC |
Greene Barry EPresident
|
Exercise / conversionCommon Stock | 58,913 | $16.43 | $967,940.59 |
DisclosureSEC source: 0001735276-19-000094 · edgardoc.xml · nonDerivative · entry 1 Greene Barry E · CIK 0001291963 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,851 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 14, 2019. The 58,913 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 49,456 | $0.00 Strike: $16.43 | $0.00 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · derivative · entry 6 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,456 shares Expires 2019-12-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. F6 · derivative.exercise_date: The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 1,870 | $80.31 | $150,179.70 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · nonDerivative · entry 4 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,993 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. F4 · price: Sale prices ranged from $80.28 to $80.44 Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 26,754 | $79.80 | $2,134,969.20 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · nonDerivative · entry 3 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,863 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. F3 · price: Sale prices ranged from $79.27 to $80.26 Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
SaleCommon Stock | 20,832 | $78.92 | $1,644,061.44 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · nonDerivative · entry 2 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,617 F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. F2 · price: Sale prices ranged from $78.27 to $79.26 Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:06 UTC |
MARAGANORE JOHNDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 49,456 | $16.43 | $812,562.08 |
DisclosureSEC source: 0001735276-19-000092 · edgardoc.xml · nonDerivative · entry 1 MARAGANORE JOHN · CIK 0001180432 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 11, 2019. The 49,456 options exercised and sold by the reporting person were due to expire on December 9, 2019. Read SEC document |
| October 10, 2019 Filed Nov 26, 2019 21:07 UTC |
KEATING LAURIEEVP, Chief Legal Officer
|
OtherCommon Stock | 10 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-19-000109 · edgardoc.xml · nonDerivative · entry 1 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 434 F1 · kind: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F1 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| October 10, 2019 Filed Apr 21, 2021 22:22 UTC |
Poulton Jeffrey V.Chief Financial Officer
|
OtherCommon Stock | 38 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-21-000040 · edgardoc.xml · nonDerivative · entry 4 Poulton Jeffrey V. · CIK 0001782962 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · by Managed Account Disclosed balance after: 38 F3 · kind: Reflects shares of ALNY common stock acquired by the reporting person on October 10, 2019 under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. This acquisition and indirect holding was inadvertently omitted from previously filed Form 4 reports. F4 · price: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. F4 · ownership.nature: Reflects shares of ALNY common stock acquired by the reporting person under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:17 UTC |
Greenstreet YvonneChief Operating Officer
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000087 · edgardoc.xml · derivative · entry 3 Greenstreet Yvonne · CIK 0001446125 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F2 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:17 UTC |
KEATING LAURIEEVP, Chief Legal Officer
|
GrantPerformance Stock Option 2016 (right to buy) · Derivative | 6,250 | $0.00 Strike: $42.22 | $0.00 |
DisclosureSEC source: 0001735276-19-000086 · edgardoc.xml · derivative · entry 4 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-12-20 F3 · kind: On December 20, 2016, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development, regulatory or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 20:17 UTC |
KEATING LAURIEEVP, Chief Legal Officer
|
GrantPerformance Stock Option 2015 (right to buy) · Derivative | 3,500 | $0.00 Strike: $88.95 | $0.00 |
DisclosureSEC source: 0001735276-19-000086 · edgardoc.xml · derivative · entry 3 KEATING LAURIE · CIK 0001620743 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 3,500 shares Expires 2025-12-18 F2 · kind: On December 18, 2015, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock. One quarter of the shares subject to the option vested upon the achievement of each of four specific clinical development or commercial events, as approved by our compensation committee. The compensation committee of the Company determined that the fourth performance criterion was met effective as of August 6, 2019 and the option vested as to the final one-quarter of the shares as of such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.